Skip to content
Catalyst

PapersPMID:33081717

A hypocaloric high-protein diet supplemented with β-cryptoxanthin improves non-alcoholic fatty liver disease: a randomized controlled trial.

BMC gastroenterology2020The record ↗

  1. Finding, moderate evidencelowersAlanine aminotransferase

What moved

1 findingHow to read these marks →
  • “In addition, patients in the β-cryptoxanthin group only showed a greater 12-week reduction in serum level of ALT, compared to those in the control group (for ALT: mean difference − 9.6 IU/L; p = 0.005).”
    Study
    RCT
    Duration
    3 months
    Effect
    −9.6 mean difference
    Dose studied
    6 mg/day β-cryptoxanthin, one 600 mg capsule (powder 1% β-cryptoxanthin, 99% starch) daily after dinner, 12 weeks
    Population
    Iranian overweight/obese adults with moderate-to-severe non-alcoholic fatty liver disease; the same 500 kcal/day-deficit normal-protein diet in both arms; intention-to-treat, multivariable-adjusted ANCOVA contrast against the control arm

Study record

Design
randomised controlled trial
Species
human
Population
overweight/obese adult non-alcoholic fatty liver disease (NAFLD) outpatients with grade 2-3 hepatic steatosis, Ahvaz, Iran
Participants
92
Comparator
placebo
Duration
84 days
Endpoints measured
33